Mesoglycan: clinical evidences for use in vascular diseases

Antonella Tufano, Claudia Arturo, Ernesto Cimino, Matteo Nicola Dario Di Minno, Mirko Di Capua, Anna Maria Cerbone, Giovanni Di Minno, Antonella Tufano, Claudia Arturo, Ernesto Cimino, Matteo Nicola Dario Di Minno, Mirko Di Capua, Anna Maria Cerbone, Giovanni Di Minno

Abstract

Vascular glycosaminoglycans (GAG) are essential components of the endothelium and vessel wall and have been shown to be involved in several biologic functions. Mesoglycan, a natural GAG preparation, is a polysaccharide complex rich in sulphur radicals with strong negative electric charge. It is extracted from porcine intestinal mucosa and is composed of heparan sulfate, dermatan sulfate, electrophoretically slow-moving heparin, and variable and minimal quantities of chondroitin sulfate. Data on antithrombotic and profibrinolytic activities of the drug show that mesoglycan, although not indicated in the treatment of acute arterial or venous thrombosis because of the low antithrombotic effect, may be useful in the management of vascular diseases, when combined with antithrombotics in the case of disease of cerebral vasculature, and with antithrombotics and vasodilator drugs in the case of chronic peripheral arterial disease. The protective effect of mesoglycan in patients with venous thrombosis and the absence of side effects, support the use of GAG in patients with chronic venous insufficiency and persistent venous ulcers, in association with compression therapy (zinc bandages, multiple layer bandages, etc.), elastic compression stockings, and local care, and in the prevention of recurrences in patients with previous DVT following the standard course of oral anticoagulation treatment.

References

    1. Vittoria A, Messa GL, Frigerio C, Celasco G, Auteri A. Effect of a single dose of mesoglycan on the human fibrinolytic system, and the profibrinolytic action of nine daily doses. International Journal of Tissue Reactions. 1988;10(4):261–266.
    1. Maggi A, Abbadini M, Pagella PG, Borowska A, Pangrazzi J, Donati MB. Antithrombotic properties of dermatan sulphate in a rat venous thrombosis model. Haemostasis. 1987;17(6):329–335.
    1. Teien AN, Abildgaard U, Hook M. The anticoagulant effect of heparin sulfate and dermatan sulfate. Thrombosis Research. 1976;8(6):859–867.
    1. Abbadini M, Zhu GJ, Maggi A, Pangrazzi J, Donati MB, Mussoni L. Dermatan sulphate induces plasminogen activator release in the perfused rat hindquarters. Blood. 1987;70(6):1858–1860.
    1. Restori G, Boiardi L, Mari S, et al. Glycosaminoglycans administration (heparan sulphate, dermatan-sulphate and their combinations 50:50) and reduction of atherosclerosis progression rate in rabbits with a diet-induced hypercholesterolemia. Atherosclerosis and Cardiovascular Disease. 1989;4:971–975.
    1. Blajchman MA, Young E, Ofosu FA. Effects of unfractionated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits. Annals of the New York Academy of Sciences. 1989;556:245–254.
    1. Caimi G, Romandini S, Lo Presti R, et al. Effect of mesoglycan on macrorheologic and microrheologic parameters. Current Therapeutic Research. 1992;52(3):412–418.
    1. Viliani T, Scarselli M, Pieri A, Gatti M, Santini M, Pasquetti P. Pharmacological treatment of mechanical edema: a randomized controlled trial about the effects of mesoglycan. European Journal of Physical and Rehabilitation Medicine. 2009;45(1):21–29.
    1. Tardieu M, Bourin M-C, Desgranges P, Barbier P, Barritault D, Caruelle J-P. Mesoglycan and sulodexide act as stabilizers and protectors of fibroblast growth factors (FGFs) Growth Factors. 1994;11(4):291–300.
    1. Lotti T, Celasco G, Tsampau D, et al. Mesoglycan treatment restores defective fibrinolytic potential in cutaneous necrotizing venulitis. International Journal of Dermatology. 1993;32(5):368–371.
    1. Orefice G, Brancaccio V, Coppola G, et al. Comparative effects of mesoglycan and ticlopidine treatment on some coagulative parameters in patients with previous ischemic stroke: results of a randomized controlled trial. Current Therapeutic Research. 2002;63(5):337–343.
    1. Orefice G, Troisi E, Selvaggio M, et al. Effect of long-term mesoglycan treatment on fibrinogen plasma levels in patients with ischemic cerebrovascular disease. Current Therapeutic Research. 1992;52(5):666–670.
    1. Vecchio F, Zanchin G, Maggioni F, Santambrogio C, De Zanche L. Mesoglycan in treatment of patients with cerebral ischemia: effects of hemorheologic and hematochemical parameters. Acta Neurologica. 1993;48(6):449–456.
    1. Mansi D, Sinisi L, De Michele G, et al. Open trial of mesoglycan in the treatment of cerebrovascular ischemic disease. Acta Neurologica. 1988;43(2):108–112.
    1. Forconi S, Battistini N, Guerrini N, Passero GS. A randomized, ASA-controlled trial of mesoglycan in secondary prevention after cerebral ischemic events. Cerebrovascular Diseases. 1995;5:334–341.
    1. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K. Fibrinogen as a risk factor for stroke and myocardial infarction. The New England Journal of Medicine. 1984;311(8):501–505.
    1. Di Minno G, Mancini M. Drugs affecting plasma fibrinogen levels. Cardiovascular Drugs and Therapy. 1992;6(1):25–27.
    1. Andreozzi GM, Signorelli S, Lo Duca S, et al. Effects of mesoglycan sulfate on the arterial elastic module. Angiology. 1987;38(8):593–600.
    1. Raso AM, Maggio D, Trogolo M, et al. Effectiveness of mesoglycan therapy in patients with ischemia of the lower limbs. Preliminary results of a new therapeutic protocol. Minerva Cardioangiologica. 1997;45(7-8):383–392.
    1. Nenci GG, Gresele P, Ferrari G, Santoro L, Gianese F. Treatment of intermittent claudication with mesoglycan—a placebo-controlled, double-blind study. Thrombosis and Haemostasis. 2001;86(5):1181–1187.
    1. Nakashima Y, Segawa J, Kawashima T, Fukuchi Y, Kuroiwa A. Chronic arterial occlusion with PGE1-resistant skin lesions treated by glycosaminoglycan compound—case reports. Angiology. 1990;41(9):731–736.
    1. Segawa J, Kawashima T, Yashiro A, et al. Acute effects of intravenous administration of glycosaminoglycans compound (FPFD 101) on healthy volunteers. Journal of Japan Atherosclerosis Society. 1988;16:p. 871.
    1. Arosio E, Ferrari G, Santoro L, Gianese F. A placebo-controlled, double-blind study of mesoglycan in the treatment of chronic venous ulcers. European Journal of Vascular and Endovascular Surgery. 2001;22(4):365–372.
    1. Andreozzi GM. Effectiveness of mesoglycan in patients with previous deep venous thrombosis and chronic venous insufficiency. Minerva Cardioangiologica. 2007;55(6):741–753.
    1. Viliani T, Scarselli M, Pieri A, Gatti M, Santini M, Pasquetti P. Pharmacological treatment of mechanical edema: a randomized controlled trial about the effects of mesoglycan. European Journal of Physical and Rehabilitation Medicine. 2009;45(1):21–29.
    1. Prandoni P, Cattelan AM, Carta M. Long-term sequelae of deep-vein thrombosis of the lower limbs. Experience with mesoglycan. Annali Italiani di Medicina Interna. 1989;4(4):378–385.
    1. Kurz X, Kahn SR, Abenhaim L, et al. Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis and management. Summary of an evidence-based report of the VEINES task force. Venous Insufficiency Epidemiologic and Economic Studies. International Angiology. 1999;18(2):83–102.
    1. van de Scheur M, Falanga V. Pericapillary fibrin cuffs in venous disease: a reappraisal. Dermatologic Surgery. 1997;23(10):955–959.
    1. Penc SF, Pomahac B, Winkler T, et al. Dermatan sulfate released after injury is a potent promoter of fibroblast growth factor-2 function. Journal of Biological Chemistry. 1998;273(43):28116–28121.
    1. McGrath JA, Eady RAJ. Heparan sulphate proteoglycan and wound healing in skin. Journal of Pathology. 1997;183(3):251–252.
    1. Mariani F. Edema of the lower limb: differential diagnosis and therapy. Italian Journal of Practice Cardiology. 2004;2:61–69.
    1. Terry M, O’Brien SP, Kerstein MD. Lower-extremity edema: evaluation and diagnosis. Wounds. 1998;10(4):118–124.
    1. Padberg FT, Jr., Johnston MV, Sisto SA, Burnand KG, Wakefield TW, Perkowski P. Structured exercise improves calf muscle pump function in chronic venous insufficiency: a randomized trial. Journal of Vascular Surgery. 2004;39(1):79–87.
    1. Coccheri S, Scondotto G, Agnelli G, Aloisi D, Palazzini E, Zamboni V. Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers. Thrombosis and Haemostasis. 2002;87(6):947–952.
    1. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition) Chest. 2008;133(6):454S–545S.
    1. Pesavento R, Villalta S, Prandoni P. The post-thrombotic syndrome. Internal and Emergency Medicine. 2010;5(3):185–192.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅